European innovation initiative puts Novo, Sanofi, and Eli Lilly in the same room

Novo Nordisk is participating in a public-private, European initiative, under which the firm has to share data with some of its biggest competition. Being a partner and a competitor can be a balancing act, according to Novo VP Matthias Müllenborn.
Matthias Müllenborn, vice president for study programs, patients and partnerships at Novo Nordisk | Photo: Ulrich Quistgaard
Matthias Müllenborn, vice president for study programs, patients and partnerships at Novo Nordisk | Photo: Ulrich Quistgaard
by ulrich quistgaard, translated by daniel pedersen

Novo Nordisk sees clear advantages from being part of the new public-private, European partnership, dubbed the Innovative Health Initiative (IHI), which brings the EU and the life science industry closer to each other with a budget of EUR 2.4bn.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading